NYSE:CATX Perspective Therapeutics (CATX) Stock Price, News & Analysis $2.45 +0.04 (+1.66%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$2.44 -0.01 (-0.41%) As of 07:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Perspective Therapeutics Stock (NYSE:CATX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CATX alerts:Sign Up Key Stats Today's Range$2.31▼$2.4650-Day Range$1.71▼$2.7852-Week Range$1.60▼$19.05Volume356,994 shsAverage Volume1.03 million shsMarket Capitalization$181.42 millionP/E RatioN/ADividend YieldN/APrice Target$12.75Consensus RatingBuy Company OverviewPerspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Read More… Perspective Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreCATX MarketRank™: Perspective Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 295th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingPerspective Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.18, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePerspective Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Perspective Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Perspective Therapeutics are expected to decrease in the coming year, from ($0.88) to ($1.20) per share.Price to Book Value per Share RatioPerspective Therapeutics has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Perspective Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CATX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPerspective Therapeutics does not currently pay a dividend.Dividend GrowthPerspective Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for CATX. News and Social Media3.5 / 5News Sentiment1.31 News SentimentPerspective Therapeutics has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Perspective Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for CATX on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows8 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 14% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Perspective Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $256,344.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.52% of the stock of Perspective Therapeutics is held by insiders.Percentage Held by Institutions54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Perspective Therapeutics' insider trading history. Receive CATX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CATX Stock News HeadlinesJohan M. Spoor Buys 22,026 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) StockApril 2, 2025 | insidertrades.comPerspective Therapeutics to Participate in Upcoming May Investor ConferencesMay 1 at 7:00 AM | globenewswire.comThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim Plaehn reveals how the 2025 trade war is quietly eroding dividend income — and which U.S.-focused stocks are still raising payouts.May 1, 2025 | Investors Alley (Ad)Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid TumorsApril 29 at 12:30 PM | finance.yahoo.comCritical Analysis: Perspective Therapeutics (NYSE:CATX) versus Biostage (OTCMKTS:BSTG)April 26, 2025 | americanbankingnews.comTruist Financial Sticks to Their Buy Rating for Perspective Therapeutics (CATX)April 23, 2025 | markets.businessinsider.comPerspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual MeetingApril 23, 2025 | globenewswire.comPerspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial ResultsApril 17, 2025 | globenewswire.comSee More Headlines CATX Stock Analysis - Frequently Asked Questions How have CATX shares performed this year? Perspective Therapeutics' stock was trading at $3.19 at the start of the year. Since then, CATX shares have decreased by 23.2% and is now trading at $2.45. View the best growth stocks for 2025 here. How were Perspective Therapeutics' earnings last quarter? Perspective Therapeutics, Inc. (NYSE:CATX) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21). The company earned $0.37 million during the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative trailing twelve-month return on equity of 27.40%. When did Perspective Therapeutics' stock split? Perspective Therapeutics shares reverse split on Monday, June 17th 2024. The 1-10 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Perspective Therapeutics' major shareholders? Top institutional shareholders of Perspective Therapeutics include Bank of New York Mellon Corp (0.22%) and Taylor & Morgan Wealth Management LLC (0.12%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Lori A Woods, Markus Puhlmann, Robert F Williamson III, Johan M Spoor, Jonathan Robert Hunt, Juan Graham and Heidi Henson. View institutional ownership trends. How do I buy shares of Perspective Therapeutics? Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Perspective Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Perspective Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Chevron (CVX). Company Calendar Last Earnings11/12/2024Today4/30/2025Next Earnings (Estimated)5/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:CATX Previous SymbolNYSE:CATX CIK728387 Webwww.perspectivetherapeutics.com Phone206-676-0900Fax509-267-3670Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$12.75 High Stock Price Target$20.00 Low Stock Price Target$5.00 Potential Upside/Downside+420.4%Consensus RatingBuy Rating Score (0-4)3.18 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,510,000.00 Net Margins-4,096.66% Pretax Margin-3,780.02% Return on Equity-27.40% Return on Assets-23.16% Debt Debt-to-Equity RatioN/A Current Ratio9.60 Quick Ratio9.60 Sales & Book Value Annual Sales$1.43 million Price / Sales126.87 Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book0.92Miscellaneous Outstanding Shares74,051,000Free Float65,209,000Market Cap$181.42 million OptionableOptionable Beta1.20 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NYSE:CATX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.